Results 21 to 30 of about 52,862 (295)
Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. [PDF]
, 2013 Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore analgesic drugs and joint ...
Smith, Toby O +15 more
core +1 more source
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
, 2010 Bisphosphonates are the leading drugs for the treatment of osteoporosis. In randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ...
Graham Russell +4 more
core +2 more sources
Bisphosphonate nephrotoxicity [PDF]
Kidney International, 2008 Bisphosphonates are valuable agents for the treatment of post-menopausal osteoporosis (PMO), hypercalcemia of malignancy, and osteolytic bone metastases. Oral bisphosphonates are used mainly to treat PMO and are not associated with significant nephrotoxicity.
Perazella, Mark A., Markowitz, Glen S.
openaire +2 more sources
, 2020 Combining the properties of organic and inorganic moieties with high surface areas and pore volumes offers endless possibilities to design materials adapted to a wide range of advanced applications.
Yanhui Wang (108090) +2 more
core +1 more source
Pharmacy, 2018 Oral bisphosphonates are the first choice of therapy to reduce the risk of osteoporotic fractures. These medications have generally poor oral bioavailability, which may further be reduced by concomitant intake of certain foods and drugs; therefore, it is
Linnea Abramsson, Maria Gustafsson
doaj +1 more source
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. [PDF]
PLoS ONE, 2011 BACKGROUND: Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic drugs.
Longxiang Shen +5 more
doaj +1 more source
Pharmacology of bisphosphonates [PDF]
British Journal of Clinical Pharmacology, 2019 The biological effects of the bisphosphonates (BPs) as inhibitors of calcification and bone resorption were first described in the late 1960s. In the 50 years that have elapsed since then, the BPs have become the leading drugs for the treatment of skeletal disorders characterized by increased bone resorption, including Paget's disease of bone, bone ...
Cremers, S. +4 more
openaire +3 more sources
Therapeutic Advances in Medical Oncology, 2019 Background: Adjuvant bisphosphonates reduce the rate of breast cancer recurrence in the bone and improve breast cancer survival. However, the risk of adverse events associated with bisphosphonate therapy for breast cancer remains poorly defined. Methods:
Yan-Li Yang +4 more
doaj +1 more source
Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back
Journal of Pharmacy & Pharmaceutical Sciences, 2012 Purpose. Bisphosphonates are the main class of drugs widely used in prevention and treatment of osteoporosis. Along with the beneficial effects, recent studies point to the harms of long-term treatment with bisphosphonates. Methods.
Pooneh Salari, Mohammad Abdollahi
doaj +1 more source
Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect.
Marwa Mohsen +4 more
doaj +1 more source